Key Metrics
Factor Lens
Seasonal Performance
Dividends
Per-share amounts adjusted for stock splits.
Last 12 Payouts
| Period | Ex-Date | Amount / Share |
|---|---|---|
| Q2 2026 | ~2026-09-29 | $0.8200 |
| Q1 2026 | ~2026-06-29 | $0.8200 |
| Q2 2026 | ~2026-03-30 | $0.8200 |
| Q4 2025 | ~2025-12-30 | $0.7900 |
| Q3 2025 | ~2025-09-29 | $0.7900 |
| Q1 2025 | ~2025-06-27 | $0.7900 |
| Q2 2025 | ~2025-03-28 | $0.7900 |
| Q4 2024 | ~2024-12-30 | $0.7700 |
| Q3 2024 | ~2024-09-27 | $0.7700 |
| Q1 2024 | ~2024-06-27 | $0.7700 |
| Q2 2024 | ~2024-03-28 | $0.7700 |
| Q4 2023 | ~2023-12-28 | $0.7500 |
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Gilead Sciences, Inc. is a research-based biopharmaceutical company with a mission to discover, develop and deliver innovative therapeutics for people with life-threatening… diseases. The company operates through multiple therapeutic areas: (1) HIV, where Gilead is a leader in treatment and prevention with products including Biktarvy (the most-prescribed HIV treatment regimen), Descovy for PrEP, and Yeztugo (the first twice-yearly HIV PrEP); (2) Oncology, with products such as Trodelvy for metastatic triple-negative breast cancer and investigational cell therapies like anito-cel; (3) Liver Disease, including Livdelzi for primary biliary cholangitis and Vemlidy for chronic hepatitis B; and (4) Inflammation and other therapeutic areas. In 2025, the company generated total product sales of $28.9 billion, with HIV product sales of $20.8 billion representing 6% year-over-year growth. Gilead maintains a pipeline of 53 clinical-stage programs as of the end of 2025, with potential for up to 10 ongoing and near-term product or indication launches by the end of 2027. The company is committed to expanding global access to its medicines and announced partnerships with PEPFAR and the Global Fund to supply lenacapavir for HIV prevention to up to two million people in low- and lower-middle-income countries.
- Name
- Gilead Sciences, Inc.
- Industry
- Biotechnology
- CEO
- Daniel P. O'Day · Chairman and Chief Executive Officer
- Employees
- —
- IPO Date
- 2017-11-20
- Phone
- 6505743000
- Address
- 333 Lakeside Drive, Foster City, CA 94404
- Website
- www.gilead.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Kelly A. Kramer | Director | — |
| Sandra J. Horning | Director | — |
| Jeffrey A. Bluestone | Director | — |
| Jacqueline K. Barton | Director | — |
| Daniel P. O'Day | Chairman and Chief Executive Officer | — |
Latest News
- 2026-04-26
- 2026-04-26
- 2026-04-25
- 2026-04-24
- 2026-04-24
- 2026-04-23
- 2026-04-22
- 2026-04-21